Bart Barlogie

High Impact

Researcher

UAMS primary UA Little Rock University of Arkansas

Also affiliated: École Centrale de Nantes (1995); Northwestern University (2005); University of North Carolina at Chapel Hill (2005); Creighton University (2007–2009); Texas Tech University (2002); University of Maryland, Baltimore (2002–2003); Cedars-Sinai Medical Center (2002–2005); Grant Medical Center (2002); National Institutes of Health (1998); Arkansas Children's Hospital (1998–2006); Loyola University Medical Center (1999); Cleveland Clinic (2004); Mount Sinai Hospital (2016–2020); Hackensack University Medical Center (2003); Mayo Clinic (2002–2010); Memorial Sloan Kettering Cancer Center (2003–2010); The University of Texas MD Anderson Cancer Center (1980–2000); Harvard University (2003); University of Arizona (2002); University of Puget Sound (2001); University of Alberta (2004); Eastern Virginia Medical School (1996); The University of Texas System (1976–2009); The University of Texas at San Antonio Health Science Center (2001); Duke University (2009); National and Kapodistrian University of Athens (2015); Medical College of Wisconsin (2003); Max Delbrück Center (2006); Cornell University (2001–2010); Heidelberg University (2015); University of Münster (1976); University of Pavia (2003); Louisiana State University in Shreveport (2002); University of Arkansas Medical Center (1991–2018); Harvard University Press (2008); University Hospital Heidelberg (2015); Saint Vincent Health System (2003–2005); Henry Ford Hospital (2001); Christian-Albrechts-Universität zu Kiel (1994); Yale University (2009); University of Chicago (2004); Eastern Cooperative Oncology Group (2012); Institut National de Recherche en Santé Publique (2003); Northwestern Memorial Hospital (2005); Fred Hutch Cancer Center (1997–2012); The Barbara Ann Karmanos Cancer Institute (2006–2009); Arkansas Cardiology (1997–1998); Mount Sinai Medical Center (2018–2020); Assistance Publique – Hôpitaux de Paris (2003); Central Arkansas Veterans Healthcare System (2001–2002); Cancer Research And Biostatistics (2001–2015); Mount Sinai Hospital (2016–2021); University Hospital Münster (1975); Dana-Farber Cancer Institute (2003–2009); Centre Norbert Elias (2006); Myeloma UK (2007–2018); Signal Genetics (United States) (2012); Mayo Clinic in Arizona (2000–2005); Duke Medical Center (2009); Tisch Hospital (2016–2020); Cancer Research Center (1994–2007); Winthrop Rockefeller Foundation (2008–2024); Harrington Cancer Center (2002); Frederick National Laboratory for Cancer Research (1997); Leukemia Research Foundation (2004); The Institute of Statistical Mathematics (2012); Anderson Hospital (1976–2009); National Cancer Institute (1992–2012); Children's Hospital of The King's Daughters (1996); Alexander & Margaret Stewart Trust (2009); Nelson Engineering (United States) (2009); Mayo Clinic in Florida (2003); Millennium Engineering and Integration (United States) (2005); Center for Cancer Research (1997–1999); Erasmus MC Cancer Institute (2019); The US Oncology Network (2009); Institute for Myeloma & Bone Cancer Research (2002–2009); Alta Bates Summit Medical Center (2005); John L. McClellan Memorial Veterans Hospital (1997); Spanish Head & Neck Cancer Cooperative Group (2005); Hôpital Claude Huriez (2023); International Myeloma Foundation (2015); Arkansas Department of Agriculture (2001–2014); Columbus Community Clinical Oncology Program (2002); SWOG Cancer Research Network (2000–2009); Best Biotech (2009); University of Arizona Cancer Center (2002); Tisch Cancer Institute (2017–2020); Bristol-Myers Squibb (Switzerland) (2001–2006); University of Oklahoma Health Sciences Center (2005–2010); Drexel University (2010); University of Tennessee at Knoxville (2004); Rockefeller University (2003–2009); University of California, Davis (2001); The University of Texas at Austin (1985); Science Applications International Corporation (United States) (1997); Rotterdam University of Applied Sciences (1984); Texas Tech University Health Sciences Center (2002); University of Bologna (2006); Icahn School of Medicine at Mount Sinai (2015–2022)

Faculty Researcher

139 h-index 1152 pubs 76,839 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Bart Barlogie's research focuses on the molecular and spatial evolution of multiple myeloma, investigating the pathways from precursor conditions to advanced disease states. His work examines the genetic and transcriptional profiles associated with disease progression and relapse, seeking to identify molecular markers that predict risk. Recent publications explore the molecular underpinnings of smoldering myeloma, the spatio-temporal evolution of the disease, and the single-cell architecture of myeloma and its microenvironment.

Additional research interests include the role of specific genes, such as CST6, in suppressing bone disease associated with multiple myeloma and the development of prognostic scoring systems for patients with newly diagnosed multiple myeloma. Barlogie also investigates the feasibility of outpatient stem cell transplantation for multiple myeloma and factors influencing hospital admission. He leads a research group and has a significant publication record, with a high citation count and h-index of 138. His key collaborators at the University of Arkansas for Medical Sciences include Fenghuang Zhan, Maurizio Zangari, Sharmilan Thanendrarajan, and John D. Shaughnessy.

Metrics

h-index: 139
Publications: 1152
Citations: 76,839

Selected Publications

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

2 citations DOI OpenAlex
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024)

17 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

8 citations DOI OpenAlex
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211 (2023)

2 citations DOI OpenAlex
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023)

3 citations DOI OpenAlex
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level (2023)

30 citations DOI OpenAlex
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)

13 citations DOI OpenAlex
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023)

1 citation DOI OpenAlex
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022)

65 citations DOI OpenAlex
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)

23 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

13 citations DOI OpenAlex
N-Cadherin Stabilizes β-Catenin and Promotes β-Catenin/TCF Transcriptional Activation and Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma (2021)

2 citations DOI OpenAlex
High‐risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse (2021)

9 citations DOI OpenAlex